Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: A cross-sectional study

European Journal of Clinical Investigation

Volumn 41, Issue 10, 2011, Pages 1037-1046

  Furuzawa Carballeda, Janette ^a   Lima, Guadalupe ^a   Jakez Ocampo, Juan ^a   Llorente, Luis ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

CD8 CD123 IDO cells; Indoleamine 2,3 dioxygenase; Rheumatoid arthritis; Systemic lupus erythematosus; Th17; Tregs

Indexed keywords

CD123 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD8ALPHA ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17 ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL;

ADULT; AGED; ANTIGENS, CD14; ANTIGENS, CD8; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECEPTORS, IGG; STATISTICS AS TOPIC; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; YOUNG ADULT;

EID: 80052608888     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02491.x     Document Type: Article

References (46)

1. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci 2002;99:351-8.
2. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2, 3-dioxygenase activity in dendritic cells. J Immunol 2004;172:4100-10.
3. Pertovaara M, Raitala A, Uusitalo H, Pukander J, Helin H, Oja SS et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren's syndrome. Clin Exp Immunol 2005;142:155-61.
4. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008;181:5396-404.
5. Mulley WR, Nikolic-Paterson DJ. Indoleamine 2, 3-dioxygenase in transplantation. Nephrology 2008;13:204-11.
6. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2, 3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009;113:2394-401.
7. Popov A, Schultze J. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 2008;86:145-60.
8. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-72.
9. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2, 3-dioxygenase inhibits T cell responses. J Immunol 2002;168:3771-6.
10. Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B et al. Functional expression of indoleamine 2, 3-dioxygenase by murine CD8α+ dendritic cells. Int Immunol 2002;14:65-8.
11. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB et al. Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 2002;297:1867-70.
12. Zhu L, Ji F, Wang Y, Zhang Y, Liu Q, Zhang JZ et al. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-Mediated inhibition. J Immunol 2006;177:8226-33.
13. Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C et al. Reverse signaling through GITR ligand enables dexamethasone to active IDO in allergy. Nat Med 2007;13:579-86.
14. Puccetti P, Fallarino F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. Blood Cells Mol Dis 2008;40:101-5.
15. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-73.
16. Mellor AL, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003;170:5809-13.
17. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev Immunol 2004;4:762-4.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Prevoo MLL, Van'T Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LBA, Van Riel PL. Modified disease activity scores that included twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
21. Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998;25:277-84.
22. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
23. Furst DE. Development of TNF inhibitor therapies for the treatment of rheumatoid arhtirits. Clin Exp Rheumatol 2010;28:S5-12.
24. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010;69:1603-11.
25. Zanoni I, Granucci F. The regulatory role of dendritic cells in the induction and maintenance of T-cell tolerance. Autoimmunity 2010;44:23-32.
26. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of Th17 to regulatory T cells in HIV disease. Sci Transl Med 2010;2:32-6.
27. Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP et al. Critical role of indoleamine 2, 3-dioxygenase in tumor resistance to repeat treatments with targeted IFNgamma. Mol Cancer Ther 2008;7:3859-66.
28. Furuzawa-Carballeda J, Lima G, Uribe-Uribe N, Avila-Casado C, Mancilla E, Morales-Buenrostro LE et al. High levels of IDO-expressing CD16- peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant Proc, 2010;42:3489-96.
29. Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 2010;67:625-8.
30. Ueno A, Cho S, Cheng L, Wang J, Hou S, Nakano H et al. Transient upregulation of indoleamine 2, 3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 2007;56:1686-93.
31. Ziegler-Heitbrock HWL. Heterogeneity of human blood monocytes: The CD14+ CD16+ subpopulation. Immunol Today 1996;17:424-8.
32. Randolf GJ, Sánchez-Schmitz G, Liebman RM, Schakel K. The CD16+ (FcγRIII+) subset of human monocytes preferentially become migratory dendritic cells in a model tissue setting. J Exp Med 2002;196:517-27.
33. Sánchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, Rivas-Carvalho A, Sánchez-Schmitz G. CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 2001;13:1571-81.
34. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000;165:6037-46.
35. Grohmann U, Fallarino F, Bianchi R, Belladonna ML, Vacca C, Orabona C et al. IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2, 3-dioxygenase. J Immunol 2001;167:708-14.
36. Orabona C, Puccetti P, Vacca C, Bicciato S, Luchini A, Fallarino F et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006;107:2846-54.
37. Cao W. Molecular characterization of human plasmacytoid dendritic cells. J Clin Immunol 2009;29:257-64.
38. Manlapat AK, Kahler DJ, Chandler PR, Munn DH, Mellor AL. Cell-autonomous control of interferon type I expression by indoleamine 2, 3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol 2007;37:1064-71.
39. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2, 3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol 2005;175:5601-5.
40. Pertovaara M, Hasan T, Raitala A, Oja SS, Yli-Kerttula U, Korpela M et al. Indoleamine 2, 3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 2007;150:274-8.
41. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC et al. A defect in tryptophan catabolism impairs tolerance in ninobese diabetic mice. J Exp Med 2003;198:153-60.
42. Oertelt-Prigione S, Mao TK, Selmi C, Tsuneyama K, Ansari AA, Coppel RL et al. Impaired indoleamine 2, 3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. Autoimmunity 2008;41:92-9.
43. Lande R, Giacomini E, Serafini B, Rosicarelli B, Sebastiani GD, Minisola G et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol 2004;173:2815-24.
44. Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 2009;182:7509-15.
45. González A, Varo N, Alegre E, Díaz A, Melero I. Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem 2008;45:155-97.
46. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C et al. Tryptophan catabolism generates autoimmune-preventive regulatory T cells. Transpl Immunol 2006;17:58-60.